My watch list
my.bionity.com  
Login  

Human mortality from H5N1



Human Mortality from H5N1
As of April 11 2007
Source WHO Confirmed Human Cases of H5N1
  • The thin line represents average mortality of recent cases. The thicker line represents mortality averaged over all cases.
  • According to WHO: "Assessment of mortality rates and the time intervals between symptom onset and hospitalization and between symptom onset and death suggests that the illness pattern has not changed substantially during the three years."[1]
H5N1

Human mortality from H5N1 or the human fatality ratio from H5N1 refer to the ratio of the number of confirmed human deaths resulting from confirmed cases of transmission and infection of H5N1 to the number of those confirmed cases. For example, if there are 100 confirmed cases of humans infected with H5N1 and 10 die, then there is a 10% human fatality ratio (or mortality rate). H5N1 flu is a concern due to the global spread of H5N1 that constitutes a pandemic threat. The majority of H5N1 flu cases have been reported in southeast and east Asia.

H5N1 infections in humans are generally caused by bird to human transmission of the virus. Until May 2006, the WHO estimate of the number of human to human transmission had been "two or three cases". On May 24, 2006, Dr. Julie L. Gerberding, director of the United States Centers for Disease Control and Prevention in Atlanta, estimated that there had been "at least three." On May 30, Maria Cheng, a WHO spokeswoman, said there were "probably about half a dozen," but that no one "has got a solid number."[1] A few isolated cases of suspected human to human transmission exist.[2] with the latest such case in June 2006 (among members of a family in Sumatra).[3] No pandemic strain of H5N1 has yet been found. The key point is that, at present, "the virus is not spreading efficiently or sustainably among humans."[4]

H5N1 vaccines for chickens exist and are sometimes used, although there are many difficulties that make it especially difficult to decide whether vaccination will help more than it hurts. H5N1 pre-pandemic vaccines exist in quantities sufficient to inoculate a few million people[5] and might be useful for priming to "boost the immune response to a different H5N1 vaccine tailor-made years later to thwart an emerging pandemic".[6] H5N1 pandemic vaccines and the technologies to rapidly create them are in the H5N1 clinical trials stage but cannot be verified as useful until after a pandemic strain emerges. Efforts to identify the changes that might result in a human-communicable strain have resulted in laboratory-generated H5N1 with substantially greater affinity for human cellular receptors after a change of just two of the H5 surface proteins.[7] Significantly, mouse antibodies were 10 times less potent against the mutants than against the pre-mutated viruses.[8]

Additional recommended knowledge

Contents

H5N1 cases in humans

Confirmed human cases and mortality rate of avian influenza (H5N1)
As of December 28 2007
Country Report dates edit this table

Total
2003 2004 2005 2006 2007
casesdeaths casesdeaths casesdeaths casesdeaths casesdeaths casesdeaths
 Azerbaijan   8 563%   8 563%
 Cambodia   4 4100% 2 2100% 1 1100% 7 7100%
 PR China 1 1100%   8 563% 13 862% 5 360% 27 1763%
 Djibouti   1 00%   1 00%
 Egypt   18 1056% 23 626% 41 1639%
 Indonesia   20 1365% 55 4582% 41 3688% 116 9481%
 Iraq   3 267%   3 267%
 Laos   2 2100% 2 2100%
 Myanmar   1 00% 1 00%
 Nigeria   1 1100% 1 1100%
 Thailand   17 1271% 5 240% 3 3100%   25 1768%
 Turkey   12 433%   12 433%
 Vietnam 3 3100% 29 2069% 61 1931%   8 563% 101 4747%
Total 4 4100% 46 3270% 98 4344% 115 7969% 83 5566% 34621362%
Source: World Health Organization Communicable Disease Surveillance & Response (CSR)

History

A strain of H5N1 killed chickens in 1959 in Scotland and turkeys in 1991 in England.[9] This strain was "highly pathogenic" (deadly to birds) but caused neither illness nor death in humans.[10] "The precursor of the H5N1 influenza virus that spread to humans in 1997 was first detected in Guangdong, China, in 1996, when it caused a moderate number of deaths in geese and attracted very little attention." [11] In 1997, in Hong Kong, 18 humans were infected and 6 died in the first known case of H5N1 infecting humans. [12] H5N1 had evolved from a zero mortality rate to a 33% mortality rate.

The first report, in the current wave of HPAI A(H5N1) outbreaks, was of an outbreak that began December 10 2003 in the Republic of Korea and continued for fourteen weeks. This strain caused asymptomatic infections in humans and may have died out[13], like the 1959 strain, so that its low mortality level would have little value for predicting the mortality rate of a pandemic evolving from existing HPAI A(H5N1) strains.[14] [15] The apparently extinct strain that caused human deaths from H5N1 in the Northern part of Vietnam in 2003, 2004 and 2005 also had a much lower case mortality rate than the currently existing strains.[15] Changes are occurring in H5N1 that are increasing its pathogenicity in mammals.[16][17]

From inception through 2007, the number of WHO-confirmed cases stands at 348, with 216 fatalities (as reported by the U.N. on January 3, 2008, confirming earlier deaths) reflecting a 62% fatality rate among WHO-confirmed cases.[18] These overall figures fail to bring forward fluctuations that have appeared from year to year and in particular geographic areas. In 2005, when a markedly less-lethal strain in Northern Vietnam was responsible for most of the cases reported worldwide, only 42 of 97 people confirmed by the WHO to be infected with H5N1 died -- a 43% fatality rate. Among the WHO-confirmed cases in 2006, the case fatality ratio was higher, with 79 deaths among 114 confirmed cases.[19]-- or 69%. And 58 of the 85 WHO-confirmed cases in 2007 (reported and confirmed up to January 3, 2008, but occurring in 2007), ended in death, or 68%.[20] The higher total case fatality ratio after the end of 2005 may reflect the widespread circulation in Vietnam of a less-lethal clade in 2005, which was subsequently brought under control. The change was nonetheless interpreted by some as indicating that the virus itself was becoming more deadly over time.[21] In fact, when less-virulent strains die off, the surviving strains are the more virulent. Such difficulties in interpretation underscore that the global case fatality ratio can serve as but a crude and imperfect summary of the current complex situation with its many contributing factors, and not a clear or reliable predictive tool. If and when an influenza pandemic arises from one of the currently circulating pre-pandemic strains of Asian lineage HPAI A(H5N1), the mortality rates for the resulting human adapted pandemic strain cannot be predicted with any confidence.

Existing pre-pandemic global case fatality ratio

The global case fatality ratio looks only to the official tally[22] of cases confirmed by the WHO. It takes no account of other cases, such as those appearing in press reports. Nor does it reflect any estimate of the global extent of mild, asymptomatic[23], or other cases which are undiagnosed, unreported by national governments to the WHO, or for any reason cannot be confirmed by the WHO. While the WHO's case count is clearly the most authoritative, these unavoidable limitations result in an unknown number of cases being omitted from it. The problem of overlooked but genuine cases is emphasized by occasional reports in which later serology reveals antibodies to the H5N1 infection in the blood of persons who were never known to have bird flu, and who then are confirmed by the WHO only retroactively as "cases." Press reports of such cases, often poultry handlers, have appeared in various countries. The largest number of asymptomatic cases was confirmed in 2006 among Korean workers who had assisted in massive culls of H5N1-infected poultry.[24] This relatively benign Korean strain of H5N1 has died out, and the remaining strains of H5N1 have a higher case fatality rate in humans.

Unconfirmed cases have a potentially huge impact on the case fatality ratio. This mathematical impact is well-understood by epidemiologists, and is easy to see in theory. For example, if for each confirmed case reported by the WHO we assume that there has been another mild and unreported case, the actual global number of cases would be double the current number of WHO-confirmed cases. The fatality ratio for H5N1 infections would then be calculated as the same number of deaths, but divided by a doubled number for total cases, resulting in a hypothetical death ratio of half the currently-reported fatality ratio. Such a result would indicate to epidemiologists that the world was confronting an H5N1 virus that is less-lethal than currently assumed, although possibly one that was more contagious and difficult to track.[25]

A case-fatality ratio based on an accurate and all-inclusive count of cases would be invaluable, but unfortunately it is impossible to attain. The ability to diagnose every case of H5N1 as it arises does not exist. A few reported studies have attempted to gather preliminary data on this crucial statistic, by carrying out systematic blood testing of neighbors and contacts of fatal cases in villages where there had been confirmed H5N1 fatalities. This testing failed to turn up any overlooked mild cases. [26] [27] These methodical studies of contacts provide significant evidence that the high death rate among confirmed cases in the villages where these studies were carried out cannot be simply attributed to a wholesale failure to detect mild cases. Unfortunately, these studies are likely to remain too few and sketchy to define the complex situation worldwide regarding the lethality of the varying H5N1 clades. The testing and reporting necessary for mass serology studies to determine the incidence of overlooked cases for each existing clade and strain of H5N1 worldwide would be prohibitively costly.

Hence the precise allocation of infections by the various H5N1 clades across the spectrum including lethal, serious, mild, and asymptomatic cases is likely to remain unknown in both humans and the hundreds of other species it can infect. Scientists are very concerned about what we do know about H5N1; but even more concerned about the vast amount of important data that we don't know about H5N1 and its future mutations.

A case fatality ratio of over 50% provides a grim backdrop for the fact that the currently circulating H5N1 strains have certain genetic similarities with the Spanish Influenza pandemic virus. In that pandemic, 50 million to 100 million people worldwide were killed during about a year in 1918 and 1919 [28]. The highly lethal second and third waves of the 1918 Spanish flu evolved through time into a less virulent and more transmissible human form. Although the overall fatality rate for the Spanish Flu was at most 1% to 2% of the population, the lethal waves of the Spanish Flu are not reported to have emerged with anything like the over-50% case fatality ratio observed to date in human H5N1 infection. Unfortunately, a human H5N1 pandemic might emerge with initial lethality resembling that over-50% case fatality now observed in pre-pandemic H5N1 human cases, rather than with the still-high 1-2% seen with the Spanish Flu or with the lower rates seen in the two more recent influenza pandemics.[29]

Review of patient ages and outcomes reveals that H5N1 attacks are especially lethal in pre-adults and young adults, while older victims tend to have milder attacks and to survive. [30][31] This is consistent with the frequent development of a cytokine storm in the afflicted.[32] Very few persons over 50 years of age died after suffering a H5N1 attack. Instead, the age-fatality curve of H5N1 influenza attacks in humans resembles that of the 1918 Spanish pandemic flu, and is the opposite of the mortality curve of seasonal flu strains, since seasonal influenza preferentially kills the elderly and does not kill by cytokine storm. An additional factor which may be active is that H1N1 was the predominate human flu circulating until about 1957 or 1958. Hence those over 50 years old had the opportunity to be exposed to H1N1, and to develop some immune response to the N1 group contained in that human form of flu. Likewise, annual flu vaccination includes innoculation against a type-A human H1N1 flu, leading to the possibility that the annual flu shot or FluMist innoculation might confer some immunity against H5N1 bird flu infection, and indeed testing the blood of volunteers to look for immune response to H5N1 found that some blood samples showed immunity, but more of the blood samples of persons who had received the flu shot showed an immune response.

Another factor complicating any attempt to predict lethality of an eventual pandemic strain is the variability of the resistance of human victims to the pathogen. Many human victims of the current H5N1 influenza have been blood relatives (but rarely[33] spouses) of other victims. Though this observation seemed to suggest that a familial genetic susceptibility might have played a role in human infection[34], a study by researchers at the Harvard School of public health noted no significant familial pattern of infection.[35] [36] Clearly, those whose immune systems are best able to fight off the virus are the most likely to survive a pandemic. Those with impairment of the needed immune function, whether from familial genetics or from AIDS, have poorer chances. Moreover, the health care system is generally expected to be overwhelmed throughout a pandemic. Persons needing access to medical care, whether for influenza or for unrelated serious maladies, are unlikely to receive the accustomed care, and without it their survival chances will be reduced.

Planning reports

Governments and other organizations at many levels and in many places have produced "planning" reports that, among other things, have offered speculation on the mortality rate of an eventual H5N1 pandemic. That speculation has varied widely.[37] One such report stated that "over half a million Americans could die and over 2.3 million could be hospitalized if a moderately severe strain of a pandemic flu virus hits the U.S."[38]. No one knew if "moderately severe" was an accurate guess or not. A report entitled A Killer Flu?[39] projected that, with an assumed (guessed) contraction rate of just 25%, and with a severity rate as low as that of the two lowest severity flu pandemics of the 1900s, a modern influenza A pandemic would cause 180 thousand deaths in the US, while a pandemic equaling the 1918 Spanish Flu in level of lethality would cause one million deaths in the US. Again, the report offered no evidence that an emerging H5N1 flu pandemic would be between these figures.[40]

The current avian flu, in humans, is fatal in over 50% of confirmed cases. Yet early projections like those above have assumed that such a lethal avian strain would surely lose genes contributing to its lethality in humans as it made the adaptations necessary for ready transmission in the human population. This optimistic assumption cannot be relied on. As the WHO reported in November 2006, initial outbreaks of an H5N1 pandemic could rival the current lethality of over 50%.[29] Further information necessary to make an accurate projection of initial lethality of an H5N1 pandemic does not exist, as no data was collected that could show the pre-pandemic virulence in any potential flu strain until after the last pandemic of the 20th Century. There is no basis for assuming that an H5N1 pandemic will emerge with only the far lower 1-2% lethality rate of the Spanish Flu, once assumed to be a worst case scenario. There exists no reliable prediction of the mortality rate of an H5N1 pandemic, and it would be irresponsible to confine planning to only optimistic assumptions out of step with the currently observed case fatality ratio.

Although marred by unrealistically low ranges of assumed mortality, the earlier planning reports nevertheless show convincingly that we are not prepared even for a pandemic as severe as the milder pandemics of the past century.[41], let alone the much higher case fatality ratios seen more recently.

Predicting pandemic mortality rate

Although some mammalian adaptations have been noted, H5N1 remains better adapted for infecting birds than mammallian hosts[42], which is why the disease it causes is called a bird flu. No pandemic strain of H5N1 has yet been found. The precise nature and extent of the genetic alterations that might change one of the currently circulating avian influenza strains into a human flu strain cannot be known in advance.

One especially important question is whether the H5N1 virus is likely to retain its present high lethality should it acquire an ability to spread easily from person to person, and thus start a pandemic. Should the virus improve its transmissibility by acquiring, through a reassortment event, internal human genes, then the lethality of the virus would most likely be reduced. However, should the virus improve its transmissibility through adaptation as a wholly avian virus, then the present high lethality could be maintained during a pandemic. While many of the current H5N1 strains circulating in birds can generate a dangerous cytokine storm in healthy adult humans, the ultimate pandemic strain might arise from a less-lethal strain, or its current level of lethality might be lost in the adaptation to a human host.[13][43][44][45] [46]

If H5N1 mutates so that it can jump from human to human, while maintaining a relatively high level of mortality, how many people could die? Risk communication analysts Peter M. Sandman and Jody Lanard give a round-up of the various estimates:

Worldwide mortality estimates range all the way from 2-7.4 million deaths (the “conservatively low” pandemic influenza calculation of a flu modeling expert at the U.S. Centers for Disease Control and Prevention) to 1000 million deaths (the bird flu pandemic prediction of one Russian virologist). The estimates of most H5N1 experts range less widely but still widely. In an H5N1 pandemic, the experts guess that somewhere between a quarter of us and half of us would get sick, and somewhere between one percent and five percent of those who got sick would die — the young and hale as well as the old and frail. If it's a quarter and one percent, that's 16 million dead; if it's a half and five percent, it's 160 million dead. Either way it's a big number. [47]

The renowned virus expert Robert Webster provided perhaps the most extreme estimate when he acknowledged in March 2003 that H5N1 has the theoretical capacity to mutate into a form that could kill one half of the human population,[48] stating, "Society just can't accept the idea that 50 percent of the population could die. And I think we have to face that possibility".[49]

Genetic factors

Main article: H5N1 genetic structure

H5N1 may cause more than one influenza pandemic as it is expected to continue mutating in birds regardless of whether humans develop herd immunity to a future pandemic strain.[50] Influenza pandemics from its genetic offsring may include influenza A virus subtypes other than H5N1.[51] While genetic analysis of the H5N1 virus shows that influenza pandemics from its genetic offspring can easily be far more lethal than the Spanish Flu pandemic[52], planning for a future influenza pandemic is based on what can be done and there is no higher Pandemic Severity Index level than a Category 5 pandemic which, roughly speaking, is any pandemic as bad the Spanish flu or worse; and for which all intervention measures are to be used.[53]

There "is evidence of at least three independent virulence factors connected with three different genes. It is highly unlikely that all of the high-virulence alleles will simultaneously mutate and disappear if and when the haemagglutinin gene changes so as to make the haemagglutinin molecule better adapted for the human-type (alpha-2,6-linked) receptor (which is a necessary prerequisite in order that a pandemic with H5N1 virus may start). It is more probable that evolutionary adaptation of the haemagglutinin of H5N1 viruses to the human-type receptor will happen without any simultaneous change in those other genetic properties that now are important for explaining the exceptionally high virulence of certain strains of avian-adapted H5N1 influenza virus. The change of the haemagglutinin molecule from avian adaptation to human adaptation must be expected to act as an additional virulence factor because it will enhance the total number of cells that can be infected (per host organism), increase the total rate of virus replication and potentiate the effects of the other virulence factors already present."[52] The H5N1 genes work together in ways we don't yet understand.[54] Influenza research is continuing. The genetic factors that make H5N1 so deadly are only partly understood. Known factors involve the surface antigen encoding gene segments H (hemagglutinin)[55] and N (neuraminidase) genes (causing it to be H5N1 for example), as well as the matrix M2 gene, and the polymerase genes.

"In order to cause a pandemic, H5N1 viruses will have to acquire the ability to transmit efficiently from person to person. The H5 hemagglutinin (HA) is found in influenza viruses that typically infect avian species, so efficient person-to-person spread could happen if the H5N1 virus reassorts, or exchanges genes, with circulating human influenza viruses giving rise to a virus with the H5 HA (to which the population is not immune) in a gene constellation that confers the property of transmissibility. Alternatively, efficient person-to-person spread could occur if the H5N1 virus evolves and adapts to more efficient replication and transmissibility in the human population."[56] A change of just two genes identified in laboratory testing appears to substantially increase the affinity of H5N1 for binding with human cell surface receptors.[57]

Neuraminidase is an antigenic glycoprotein enzyme found on the surface of the influenza viruses. It helps the release of progeny viruses from infected cells. Flu drugs Tamiflu and Relenza work by inhibiting some strains of neuraminidase. They were developed based on N2 and N9. "In the N1 form of the protein, a small segment called the 150-loop is inverted, creating a hollow pocket that does not exist in the N2 and N9 proteins. [...] When the researchers looked at how existing drugs interacted with the N1 protein, they found that, in the presence of neuraminidase inhibitors, the loop changed its conformation to one similar to that in the N2 and N9 proteins."[58]

The amino acid substitution (Ser31Asn) in the M2 gene in some H5N1 genotypes is associated with amantadine resistance which increases lethality. However the pathogenicity of H5N1/97 was related to the nonstructural (NS) gene. NS codes for two nonstructural proteins (NS1 and NEP). The NS1 gene of the highly pathogenic avian H5N1 viruses circulating in poultry and waterfowl in Southeast Asia is believed to be responsible for an enhanced proinflammatory cytokine response (especially TNFa) induced by these viruses in human macrophages. H5N1 NS1 is characterized by a single amino acid change at position 92. By changing the amino acid from glutamic acid to aspartic acid, researchers were able to abrogate the effect of the H5N1 NS1. This single amino acid change in the NS1 gene greatly increased the pathogenicity of the H5N1 influenza virus. This is one gebetic factor in why H5N1 is so deadly.

Polymerase encoding gene segments are also implicated in why H5N1 is so deadly. PA genes code for the PA protein, which is a critical component of the viral polymerase. The PB1 gene codes for the PB1 protein and the PB1-F2 protein. The PB1-F2 protein probably contributes to viral pathogenicity and might have an important role in determining the severity of pandemic influenza. Until H5N1, all known avian influenza viruses had a Glu at position 627, while all human influenza viruses had a lysine. Recently, some 75% of H5N1 human virus isolates identified in Vietnam had a mutation consisting of Lysine at residue 627 in the PB2 protein; a change believed associated with high levels of virulence.

Areas of research

Areas of research to identify the likelihood of rapid or slow evolution to human contagion, or for predicting the greater or lesser likelihood of a rather lethal human-adapted influenza include:

  • bird species susceptibility
  • bird migration paths
  • cell based vaccine development
  • adjuvant testing
  • human vaccine clinical trials
  • bird vaccine testing and use
  • computer simulations of pandemic spread patterns (e.g. will grounding flights help?)
  • detailed shape and gene code analysis of each of the RNA stands for as many flu virus strains as possible and making them available on a database for study
  • wild bird testing for flu viruses
  • testing humans for asymptomatic H5N1 infection
  • training exercizes in case of a pandemic

Computer simulations and direct gene manipulation have yielded inconclusive results.

Scientific advances

Scientific advances may attenuate probable lethality. The genetic lethality potential of the initial flu pandemic strain is only one important factor in determining the ultimate outcome in number of human lives lost. Another factor that grows potentially more important with the passage of time is human preparation. For example, no influenza vaccine specific to H5N1 could be produced when it emerged in Hong Kong in 1997, because it was lethal to eggs. Reverse DNA techniques have since made a vaccine possible, and several H5N1 vaccines have been tested and are in production in at least limited quantities. Vaccine development and production facilities are being ramped up, and possible pre-pandemic vaccines are being produced and studied. If a human pandemic does not emerge in the next few years, its eventual emergence may become almost a non-event if a very-effective pre-pandemic vaccine has prepared the population with sufficient herd immunity to blunt its lethality. Indeed, if there is sufficient immunity to stop it at the source, it will not become pandemic.

As long as the likelihood of protecting the population continues to rise with the passage of time, that likelihood becomes an increasingly important factor in predicting the loss of lives and the amount of economic dislocation that will ultimately occur. In light of human potential to develop herd immunity via vaccination in advance of a pandemic strain, the time that it allows us to do so before it evolves may become as crucial or more crucial to the measure of damage it causes than its own lethality and contagiousness.

Sources and notes

  1. ^ Donald G. McNeil Jr.. "Human Flu Transfers May Exceed Reports", New York Times, June 4 2006. 
  2. ^ "Seven Indonesian Bird Flu Cases Linked to Patients", Bloomberg, May 23 2006. 
  3. ^ WHO confirms human transmission< in Indonesian bird flu cluster.
  4. ^ "Avian influenza – situation in Indonesia – update 17", WHO, June 6 2006. 
  5. ^ HHS has enough H5N1 vaccine for 4 million people. CIDRAP (July 5 2006).
  6. ^ Study supports concept of 2-stage H5N1 vaccination. CIDRAP (October 13 2006).
  7. ^ http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/aug1007mutant.html Researchers create H5N1 mutations to pave way for new vaccines and treatments Aug 10, 2007 (CIDRAP News) "Focusing on genetic changes to one portion of the H5 protein, called the receptor binding domain, [the researchers] found that as few as two mutations could enhance the ability of H5N1 to recognize human cells, according to the press release." Discussing Science 10 August 2007: Vol. 317. no. 5839, pp. 825 - 828 DOI: 10.1126/science.1135165 http://www.sciencemag.org/cgi/content/abstract/317/5839/825 Immunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding Specificity Yang,Wei, et al.
  8. ^ http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/aug1007mutant.html Researchers create H5N1 mutations to pave way for new vaccines and treatments Aug 10, 2007 (CIDRAP News) "To assess how the immune system responds to the mutated H5N1 viruses the authors ran mouse studies, which revealed that mouse antibodies were 10 times less potent against the mutants." Discussing Science 10 August 2007: Vol. 317. no. 5839, pp. 825 - 828 DOI: 10.1126/science.1135165 http://www.sciencemag.org/cgi/content/abstract/317/5839/825 Immunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding Specificity Yang,Wei, et al.
  9. ^ A review of avian influenza in different bird species. Avian Virology, VLA Weybridge, Addlestone, Surrey KT15 3NB, UK.
  10. ^ "Situation (poultry) in Asia: need for a long-term response, comparison with previous outbreaks", Disease Outbreak News: Avian influenza A(H5N1), WHO, March 2 2004. Retrieved on 2006-10-27. 
  11. ^ Robert G. Webster, Malik Peiris, Honglin Chen, and Yi Guan (January 2006). H5N1 Outbreaks and Enzootic Influenza. CDC. Retrieved on 2006-10-28.
  12. ^ WHO (October 28 2005). H5N1 avian influenza: timeline.
  13. ^ a b Tan Ee Lyn (February 1 2007). "Don't ignore less virulent bird flu strains: experts". Scientific American.
  14. ^ "Five Koreans had H5N1 virus but no illness", CIDRAP, September 21 2006. 
  15. ^ a b WHO (August 18 2006). Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines. Contains latest Evolutionary "Tree of Life" for H5N1
  16. ^ Chen H, Deng G, Li Z, Tian G, Li Y, Jiao P, Zhang L, Liu Z, Webster RG, Yu K. (2004). "The evolution of H5N1 influenza viruses in ducks in southern China". Proc. Natl. Acad. Sci. U. S. A. 101 (28): 10452-10457. PubMed. Full Text
  17. ^ http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/oct0507avian.html H5N1 mutation that could help spark pandemic identified "The change promotes better viral replication at the lower temperatures found in the upper airways of mammals..."
  18. ^ http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_01_03/en/index.html Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO / 3 January 2008 For possible later updates by the WHO, see http://www.who.int/csr/disease/avian_influenza/country/en/
  19. ^ Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. WHO (December 29 2006).
  20. ^ http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_01_03/en/index.html Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO / 3 January 2008 | For possible later updates by the WHO, see http://www.who.int/csr/disease/avian_influenza/country/en/
  21. ^ H5N1 Getting Deadlier. based on the article Bird Flu Fatality Rate in Humans Climbs to 64% as Virus Spreads.
  22. ^ The tally may be obtained by clicking a link to the most current date shown by the UN on the WHO's web page entitled Epidemic and Pandemic Alert and Response (EPR) http://www.who.int/csr/disease/avian_influenza/country/en/
  23. ^ http://www.medpagetoday.com/InfectiousDisease/URItheFlu/tb/5964 Options For Influenza Control VI (Conference, Toronto Canada, June 18, 2007) Even those who were in close contact with both infected birds and infected people showed no sign of ever having been infected, Dr. Dejpichai and colleagues found. The study is consistent with findings in Hong Kong, China, and Cambodia, which showed viral seroprevalence of no more than 10% among poultry workers and people living in villages where H5N1 outbreaks occurred, she said. But it contradicts a population-based study in Vietnam, published last year, that concluded that mild cases of the virus were likely to be common. (see Mild Avian Flu Transmission May Be Common) http://www.medpagetoday.com/InfectiousDisease/URItheFlu/tb/2450
  24. ^ Five Koreans had H5N1 virus but no illness (21 September 2006). CIDRAP. Retrieved on 2006-08-23.
  25. ^ http://www.recombinomics.com/News/10030701/H5N1_Jakarta_Cluster.html H5N1 Cluster Raises Surveillance Concerns In Indonesia Recombinomics Commentary October 3, 2007 (Suggests Indonesian cases may be less lethal than feared, but more prevalent due to various under-sampling errors.) (Note: This reference needs to be replaced with a better one. Recombinomics and Henry L Niman are not credible sources according to the UN experts on bird flu.)
  26. ^ "Mild H5N1 cases weren’t found missed in Cambodian outbreak study", CIDRAP, March 27 2006. 
  27. ^ "Cambodian study suggests mild H5N1 cases are rare", CIDRAP, September 7 2006. 
  28. ^ The Threat of Pandemic Influenza: Are We Ready? Workshop Summary (2005). NAP. Retrieved on 2006-08-21.
  29. ^ a b CBC CIDRAP WHO PDF
  30. ^ Human Avian Influenza A(H5N1) Cases by Age Group and Country.
  31. ^ M. Smallman-Raynor and A.D. Cliff (March 4 2007). "Avian influenza A (H5N1) age distribution in humans [letter]". Emerg Infect Dis.
  32. ^ "Immediate Treatment Needed for Bird Flu Cases, Study Says", New York Times, September 11 2006. 
  33. ^ In the November 2005 Emerging Infectious Diseases Journal article Family Clustering of Avian Influenza A (H5N1) Sonja Olsen et al listed 15 family clusters, in which three included a husband and wife pair. (Only two of these pairs had all four members actually confirmed as H5N1 positive.) The "blood relative theory" is, so far, too weak to be called a theory. It is an observation, with some reasoning that could support it as a hypothesis (the genetic tendency possibility, for instance).
  34. ^ I. Nyoman Kandun et al. (November 23, 2006). "Three Indonesian Clusters of H5N1 Virus Infection in 2005". NEJM 355 (21): 2186-2194.
  35. ^ Little Evidence for Genetic Susceptibility to Influenza A (H5N1) from Family Clustering Data -- Virginia E. Pitzer, Sonja J. Olsen, Carl T. Bergstrom, Scott F. Dowell, and Marc Lipsitch http://www.cdc.gov/eid/content/13/7/pdfs/06-1538.pdf
  36. ^ http://www.cdc.gov/eid/content/13/7/1074.htm Volume 13, Number 7–July 2007 Dispatch Little Evidence for Genetic Susceptibility to Influenza A (H5N1) from Family Clustering Data Virginia E. Pitzer,* Comments to Author Sonja J. Olsen,† Carl T. Bergstrom,‡ Scott F. Dowell,† and Marc Lipsitch*
    • Harvard School of Public Health, Boston, Massachusetts, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA; and ‡University of Washington, Seattle, Washington, USA
    Abstract The apparent clustering of human cases of influenza A (H5N1) among blood relatives has been considered as evidence of genetic variation in susceptibility. We show that, by chance alone, a high proportion of clusters are expected to be limited to blood relatives when infection is a rare event.
  37. ^ http://www.upmc-cbn.org/report_archive/2006/06_June_2006/cbnreport_060206.html CBN Report: Severe Pandemic Planning Assumptions May Be Too Low
  38. ^ Pandemic Flu Projection Says More Than Half Million Could Die in U.S.. Senior Journal (June 24 2005).
  39. ^ Healthy Americans Full report PDF.
  40. ^ Jennifer Barrett (May 3 2006). A Dramatic Disconnect. Newsweek. Retrieved on 2006-12-11. estimates two million dead in the US, for example
  41. ^ Dr. Martin Meltzer of the Centers for Disease Control, an expert on the societal impact of diseases, warns that “There is no healthcare system anywhere in the world that can cope with even a mild pandemic like the one in 1968” Meltzer MI, Lancet Asia Forum, Singapore, May 2006
  42. ^ http://jvi.asm.org/cgi/content/abstract/81/13/6890 Inefficient Transmission of H5N1 Influenza Viruses in a Ferret Contact Model "Our results suggest that despite their receptor binding affinity, circulating H5N1 viruses retain molecular determinants that restrict their spread among mammalian species."
  43. ^ WHO working group on influenza research at the human and animal interface (November 2 2006). "Influenza research at the human and animal interface": 15. (alternate version)
  44. ^ Clinical study points to cytokine storm in H5N1 cases. CIDRAP News (September 11 2006).
  45. ^ Menno D de Jong et al (September 10 2006). "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia". Nature. Published online.
  46. ^ http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/jul1607cytokine.html Study: Inhibiting cytokine response might not reverse H5N1 infections
  47. ^ Peter M. Sandman, Jody Lanard (December 4, 2004). Pandemic Influenza Risk Communication: The Teachable Moment. Retrieved on 2006-10-08.
  48. ^ Robert Webster, Elizabeth Jane Walker (March-April 2003). "The world is teetering on the edge of a pandemic that could kill a large fraction of the human population". American Scientist 91 (2): 122. Retrieved on 2006-10-08.
  49. ^ "Renowned Bird Flu Expert Warns: Be Prepared", ABC News, March 14, 2006. Retrieved on 2006-10-08. 
  50. ^ Robert G. Webster, Ph.D., and Elena A. Govorkova, M.D., Ph.D. (November 23, 2006). "H5N1 Influenza — Continuing Evolution and Spread". NEJM 355 (21): 2174-2177.
  51. ^ CDC ARTICLE 1918 Influenza: the Mother of All Pandemics by Jeffery K. Taubenberger published January 2006
  52. ^ a b Informaworld article Why is the world so poorly prepared for a pandemic of hypervirulent avian influenza? published December 2006
  53. ^ Roos, Robert; Lisa Schnirring (February 1, 2007). HHS ties pandemic mitigation advice to severity. University of Minnesota Center for Infectious Disease Research and Policy (CIDRAP). Retrieved on 2007-02-03.
  54. ^ Ferret reassortant study
  55. ^ Science Mag
  56. ^ plosjournals Subbarao K, Luke C (2007) H5N1 Viruses and Vaccines. PLoS Pathog 3(3): e40 doi:10.1371/journal.ppat.0030040 Published: March 2, 2007
  57. ^ http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/news/aug1007mutant.html Researchers create H5N1 mutations to pave way for new vaccines and treatments Aug 10, 2007 (CIDRAP News) "Focusing on genetic changes to one portion of the H5 protein, called the receptor binding domain, [the researchers] found that as few as two mutations could enhance the ability of H5N1 to recognize human cells, according to the press release." Discussing Science 10 August 2007: Vol. 317. no. 5839, pp. 825 - 828 DOI: 10.1126/science.1135165 http://www.sciencemag.org/cgi/content/abstract/317/5839/825 Immunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding Specificity Yang,Wei, et al.
  58. ^ Scidev.net News article Bird flu protein's 'pocket' could inspire better drugs published August 16, 2006
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Human_mortality_from_H5N1". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE